Literature DB >> 23009127

The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation.

Anna M Sawka, Heather Rilkoff, Richard W Tsang, James D Brierley, Lorne Rotstein, Shereen Ezzat, Sylvia L Asa, Phillip Segal, Catherine Kelly, Afshan Zahedi, Amiram Gafni, David P Goldstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23009127     DOI： 10.1089/thy.2012.0422

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  4 in total

Review 1.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

2.  Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension.

Authors:  Anna M Sawka; Sharon Straus; Gary Rodin; Kevin E Thorpe; Shereen Ezzat; Amiram Gafni; David P Goldstein
Journal:  Trials       Date:  2015-07-14       Impact factor: 2.279

3.  Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial.

Authors:  Anna M Sawka; Sharon Straus; Gary Rodin; Lineke Heus; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Phillip Segal; Amiram Gafni; Kevin E Thorpe; David P Goldstein
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

4.  A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer.

Authors:  Anna M Sawka; Sangeet Ghai; George Tomlinson; Lorne Rotstein; Ralph Gilbert; Patrick Gullane; Jesse Pasternak; Dale Brown; John de Almeida; Jonathan Irish; Douglas Chepeha; Kevin Higgins; Eric Monteiro; Jennifer M Jones; Amiram Gafni; David P Goldstein
Journal:  BMJ Open       Date:  2018-04-12       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.